Aesthetic injectables occupy a unique regulatory space: they are neither pharmaceuticals in the classical sense nor cosmetics, but medical devices or, in the case of botulinum toxin, prescription medicines. For a clinician moving between jurisdictions, understanding which framework governs a given product — and what that framework actually requires — is not administrative background noise. It determines what a practitioner is legally permitted to inject, on whom, and with what documentation trail.
The Medical Device Regulation (EU) 2017/745
Since May 2021, dermal fillers, biostimulators, and most skin boosters sold in the European Union fall under the Medical Device Regulation (MDR), which replaced the older Medical Device Directive (MDD). The MDR was written partly in response to well-publicised device failures in unrelated product categories, and its effect on aesthetics has been to tighten classification, clinical evidence requirements, and post-market surveillance considerably.
Under the MDR, injectable fillers are classified as Class III devices — the highest risk tier, on par with implantable pacemaker leads — specifically because Rule 8 of Annex VIII treats any injectable or otherwise administered substance that is absorbed by or locally distributed in the human body as high-risk unless it falls under a lower category by virtue of being reversible and time-limited in a narrow band. In practice, most hyaluronic acid fillers, calcium hydroxylapatite, and poly-L-lactic acid products are certified as Class III, which means:
- A Notified Body (an EU-designated conformity assessment organisation) must review the technical file before a CE mark can be issued.
- Manufacturers must generate and maintain clinical evidence — not merely bench data — proportionate to the device's risk class.
- Post-market clinical follow-up (PMCF) is mandatory and ongoing, not a one-time approval event.
EUDAMED: the traceability backbone
EUDAMED, the European Database on Medical Devices, is the mechanism through which the MDR's traceability requirements are operationalised. Every device with a CE mark is assigned a Unique Device Identification (UDI) that is recorded from manufacture through distribution. For a distributor or clinic, this has a very concrete implication: every batch of filler or biostimulator that changes hands should be traceable back to its UDI, and any adverse event report should reference that identifier. This is what allows a genuine batch-level recall to be executed cleanly, rather than a blanket product withdrawal.
Students should understand that EUDAMED is being rolled out in modules and its full functionality (including public-facing search) has lagged its original timeline — but the traceability obligation on manufacturers and importers is already in force regardless of the database's completion state.
What CE marking does and does not tell you
A CE mark confirms that a device meets the essential safety and performance requirements assessed for its declared intended use. It is not a clinical efficacy ranking, nor does it certify that the product is appropriate for a use outside its labelled indication. A filler CE-marked for mid-face volumisation carries no regulatory endorsement for use in, say, penile girth augmentation unless that indication is explicitly within its technical file. Off-label use is not automatically illegal in most EU member states, but it does shift liability and informed-consent obligations onto the prescribing clinician.
Practical takeaways for the clinic
- Verify CE status and intended indication for every product before use — not just brand reputation.
- Keep batch/UDI records for every patient treatment, not only for adverse events.
- Understand that MDR compliance is a manufacturer and distributor obligation, but documentation discipline at the point of injection is what makes that compliance meaningful in practice.
- Recognise that regulatory status varies outside the EU — the same molecule may be classified and evidenced differently by the FDA, MHRA (post-Brexit UK), or TGA.